 Cara Wilson
Concepts (304)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV-1 | 33 | 2022 | 770 | 5.000 |
Why?
| | HIV Infections | 46 | 2022 | 2470 | 4.650 |
Why?
| | Intestinal Mucosa | 11 | 2021 | 528 | 3.980 |
Why?
| | CD4-Positive T-Lymphocytes | 22 | 2022 | 965 | 3.760 |
Why?
| | Gastrointestinal Microbiome | 10 | 2022 | 503 | 2.700 |
Why?
| | Dysbiosis | 8 | 2022 | 145 | 2.440 |
Why?
| | Immunity, Mucosal | 5 | 2017 | 85 | 1.970 |
Why?
| | Dendritic Cells | 12 | 2020 | 436 | 1.950 |
Why?
| | Lymphocyte Activation | 13 | 2017 | 1056 | 1.660 |
Why?
| | Bacterial Translocation | 6 | 2019 | 36 | 1.560 |
Why?
| | Interferon-gamma | 10 | 2019 | 731 | 1.520 |
Why?
| | Colon | 4 | 2022 | 233 | 1.470 |
Why?
| | Gastrointestinal Tract | 5 | 2022 | 169 | 1.430 |
Why?
| | Lymphocytes | 3 | 2021 | 342 | 1.420 |
Why?
| | Epitopes, T-Lymphocyte | 8 | 2010 | 170 | 1.310 |
Why?
| | Butyrates | 2 | 2021 | 53 | 1.300 |
Why?
| | Viremia | 6 | 2016 | 120 | 1.280 |
Why?
| | Immunity, Innate | 4 | 2021 | 734 | 1.100 |
Why?
| | Salmonella typhimurium | 2 | 2021 | 161 | 1.100 |
Why?
| | Escherichia coli | 3 | 2014 | 730 | 1.050 |
Why?
| | AIDS Vaccines | 5 | 2016 | 41 | 0.990 |
Why?
| | Granzymes | 2 | 2022 | 39 | 0.960 |
Why?
| | Th1 Cells | 2 | 2019 | 125 | 0.960 |
Why?
| | Bacteria | 4 | 2022 | 731 | 0.900 |
Why?
| | Viral Load | 11 | 2016 | 406 | 0.870 |
Why?
| | Escherichia coli Infections | 2 | 2013 | 102 | 0.820 |
Why?
| | Interleukin-23 | 2 | 2013 | 15 | 0.820 |
Why?
| | Ruminococcus | 1 | 2021 | 9 | 0.780 |
Why?
| | Acinetobacter | 1 | 2021 | 13 | 0.780 |
Why?
| | T-Lymphocytes, Cytotoxic | 4 | 2008 | 156 | 0.760 |
Why?
| | Microbiota | 5 | 2023 | 651 | 0.760 |
Why?
| | Interleukin-15 | 1 | 2021 | 76 | 0.750 |
Why?
| | Histone Deacetylase Inhibitors | 1 | 2021 | 198 | 0.690 |
Why?
| | HIV Core Protein p24 | 5 | 2006 | 28 | 0.680 |
Why?
| | Vaccines, DNA | 3 | 2016 | 30 | 0.670 |
Why?
| | Th17 Cells | 1 | 2019 | 58 | 0.670 |
Why?
| | T-Lymphocytes | 8 | 2021 | 1758 | 0.660 |
Why?
| | Immunologic Factors | 2 | 2018 | 219 | 0.660 |
Why?
| | Pyrrolidinones | 3 | 2014 | 25 | 0.660 |
Why?
| | Gram-Positive Bacteria | 1 | 2019 | 46 | 0.650 |
Why?
| | Gram-Negative Bacteria | 1 | 2019 | 67 | 0.650 |
Why?
| | Inflammation | 9 | 2021 | 2503 | 0.620 |
Why?
| | Gene Products, gag | 5 | 2007 | 36 | 0.600 |
Why?
| | Interferon Type I | 1 | 2018 | 129 | 0.590 |
Why?
| | Aging | 2 | 2020 | 1640 | 0.580 |
Why?
| | Interleukins | 1 | 2019 | 237 | 0.580 |
Why?
| | Receptors, IgG | 2 | 2014 | 66 | 0.560 |
Why?
| | Humans | 64 | 2023 | 115908 | 0.530 |
Why?
| | Ritonavir | 2 | 2013 | 72 | 0.520 |
Why?
| | Anti-HIV Agents | 5 | 2014 | 669 | 0.510 |
Why?
| | Adult | 29 | 2020 | 30820 | 0.490 |
Why?
| | Young Adult | 17 | 2020 | 10518 | 0.480 |
Why?
| | Flow Cytometry | 7 | 2017 | 1059 | 0.470 |
Why?
| | Enterobacteriaceae | 2 | 2017 | 33 | 0.470 |
Why?
| | HIV Antigens | 3 | 2016 | 17 | 0.470 |
Why?
| | Lymphocyte Subsets | 1 | 2014 | 78 | 0.460 |
Why?
| | Cells, Cultured | 9 | 2021 | 3916 | 0.460 |
Why?
| | Middle Aged | 27 | 2021 | 27084 | 0.450 |
Why?
| | Apoptosis | 2 | 2014 | 2377 | 0.440 |
Why?
| | Antiretroviral Therapy, Highly Active | 5 | 2014 | 257 | 0.430 |
Why?
| | Virus Replication | 5 | 2016 | 392 | 0.420 |
Why?
| | Sulfonamides | 2 | 2013 | 447 | 0.420 |
Why?
| | CD8-Positive T-Lymphocytes | 7 | 2016 | 686 | 0.420 |
Why?
| | Interferon-alpha | 3 | 2020 | 187 | 0.410 |
Why?
| | Killer Cells, Natural | 2 | 2016 | 379 | 0.410 |
Why?
| | Movement | 1 | 2014 | 246 | 0.400 |
Why?
| | Immunophenotyping | 6 | 2014 | 273 | 0.390 |
Why?
| | Monocytes | 1 | 2013 | 504 | 0.370 |
Why?
| | Toll-Like Receptor 8 | 1 | 2010 | 5 | 0.360 |
Why?
| | Toll-Like Receptor 7 | 1 | 2010 | 35 | 0.360 |
Why?
| | Caspase 3 | 1 | 2010 | 237 | 0.340 |
Why?
| | Interleukin-2 | 4 | 2022 | 414 | 0.340 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 1 | 2010 | 213 | 0.340 |
Why?
| | Myeloid Cells | 1 | 2010 | 127 | 0.340 |
Why?
| | RNA, Viral | 5 | 2014 | 561 | 0.330 |
Why?
| | Cytokines | 8 | 2018 | 1857 | 0.330 |
Why?
| | CD4 Lymphocyte Count | 6 | 2014 | 257 | 0.320 |
Why?
| | Interleukin-17 | 3 | 2023 | 106 | 0.320 |
Why?
| | Male | 27 | 2020 | 56128 | 0.320 |
Why?
| | Cross-Sectional Studies | 5 | 2018 | 4449 | 0.310 |
Why?
| | Phenotype | 5 | 2019 | 2861 | 0.310 |
Why?
| | Lymphoid Tissue | 1 | 2008 | 63 | 0.310 |
Why?
| | Antiviral Agents | 3 | 2020 | 648 | 0.300 |
Why?
| | Cell Proliferation | 7 | 2021 | 2196 | 0.280 |
Why?
| | Case-Control Studies | 9 | 2022 | 3054 | 0.270 |
Why?
| | Conserved Sequence | 2 | 2003 | 219 | 0.270 |
Why?
| | CD57 Antigens | 1 | 2005 | 14 | 0.270 |
Why?
| | GPI-Linked Proteins | 3 | 2016 | 54 | 0.260 |
Why?
| | Interleukin-10 | 2 | 2021 | 304 | 0.260 |
Why?
| | Female | 22 | 2020 | 60086 | 0.260 |
Why?
| | Biomarkers | 7 | 2021 | 3474 | 0.250 |
Why?
| | Aged | 12 | 2021 | 19299 | 0.250 |
Why?
| | Lipopolysaccharide Receptors | 3 | 2021 | 85 | 0.240 |
Why?
| | Leukocytes, Mononuclear | 3 | 2018 | 503 | 0.240 |
Why?
| | Cytotoxicity Tests, Immunologic | 1 | 2003 | 47 | 0.230 |
Why?
| | Viral Proteins | 1 | 2006 | 283 | 0.230 |
Why?
| | Receptors, Antigen, T-Cell | 3 | 2021 | 631 | 0.230 |
Why?
| | Chloroquine | 2 | 2016 | 52 | 0.210 |
Why?
| | Somatic Hypermutation, Immunoglobulin | 1 | 2022 | 17 | 0.210 |
Why?
| | Saccharomyces cerevisiae | 1 | 2006 | 482 | 0.210 |
Why?
| | Arthritis, Experimental | 1 | 2023 | 133 | 0.200 |
Why?
| | Yeasts | 1 | 2002 | 51 | 0.200 |
Why?
| | Blood | 1 | 2022 | 97 | 0.200 |
Why?
| | Propionates | 1 | 2021 | 33 | 0.190 |
Why?
| | Vaccines, Synthetic | 1 | 2002 | 123 | 0.190 |
Why?
| | Acquired Immunodeficiency Syndrome | 1 | 2002 | 221 | 0.190 |
Why?
| | Immunoglobulin A | 1 | 2022 | 173 | 0.190 |
Why?
| | Interferons | 1 | 2022 | 152 | 0.190 |
Why?
| | Acetates | 1 | 2021 | 95 | 0.190 |
Why?
| | Acetylation | 1 | 2021 | 212 | 0.190 |
Why?
| | Genetic Vectors | 1 | 2002 | 297 | 0.180 |
Why?
| | Interferon-beta | 1 | 2020 | 80 | 0.180 |
Why?
| | Immunologic Memory | 3 | 2009 | 312 | 0.180 |
Why?
| | Immune Tolerance | 2 | 2014 | 331 | 0.180 |
Why?
| | Bacteria, Anaerobic | 1 | 2020 | 20 | 0.180 |
Why?
| | Immunity, Humoral | 2 | 2022 | 111 | 0.170 |
Why?
| | Adaptive Immunity | 1 | 2021 | 157 | 0.170 |
Why?
| | Gene Expression Profiling | 4 | 2020 | 1548 | 0.170 |
Why?
| | Receptors, G-Protein-Coupled | 1 | 2021 | 193 | 0.170 |
Why?
| | Shoulder | 1 | 2020 | 86 | 0.170 |
Why?
| | Receptors, Cell Surface | 1 | 2021 | 358 | 0.170 |
Why?
| | Simian Acquired Immunodeficiency Syndrome | 1 | 2019 | 69 | 0.170 |
Why?
| | Raltegravir Potassium | 3 | 2014 | 16 | 0.170 |
Why?
| | Phylogeny | 2 | 2017 | 802 | 0.160 |
Why?
| | Transcriptome | 2 | 2022 | 742 | 0.160 |
Why?
| | Lymphocyte Depletion | 2 | 2012 | 115 | 0.160 |
Why?
| | Proteome | 1 | 2022 | 345 | 0.160 |
Why?
| | Diet, High-Fat | 1 | 2019 | 225 | 0.160 |
Why?
| | Feces | 2 | 2019 | 374 | 0.160 |
Why?
| | T-Cell Antigen Receptor Specificity | 3 | 2006 | 41 | 0.150 |
Why?
| | Antigens, CD | 4 | 2016 | 443 | 0.150 |
Why?
| | Microbial Interactions | 1 | 2017 | 14 | 0.150 |
Why?
| | Cell Differentiation | 3 | 2011 | 1707 | 0.150 |
Why?
| | DNA, Ribosomal | 1 | 2017 | 80 | 0.140 |
Why?
| | Interleukin-1beta | 1 | 2019 | 370 | 0.140 |
Why?
| | Chronic Disease | 5 | 2010 | 1602 | 0.140 |
Why?
| | Fungi | 1 | 2017 | 124 | 0.140 |
Why?
| | Histones | 1 | 2021 | 539 | 0.140 |
Why?
| | Anti-Retroviral Agents | 1 | 2018 | 207 | 0.130 |
Why?
| | Darunavir | 2 | 2013 | 18 | 0.130 |
Why?
| | DNA, Bacterial | 1 | 2017 | 308 | 0.130 |
Why?
| | Interleukin-12 | 1 | 2016 | 110 | 0.130 |
Why?
| | Age Factors | 2 | 2019 | 2912 | 0.130 |
Why?
| | Cluster Analysis | 1 | 2017 | 466 | 0.130 |
Why?
| | Arthritis, Rheumatoid | 1 | 2023 | 1004 | 0.130 |
Why?
| | Colitis | 1 | 2017 | 226 | 0.130 |
Why?
| | Rifamycins | 1 | 2014 | 5 | 0.120 |
Why?
| | In Vitro Techniques | 2 | 2014 | 1044 | 0.120 |
Why?
| | Biopsy | 1 | 2018 | 1056 | 0.120 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2017 | 492 | 0.120 |
Why?
| | T-Lymphocyte Subsets | 3 | 2007 | 383 | 0.120 |
Why?
| | Aged, 80 and over | 3 | 2021 | 6438 | 0.120 |
Why?
| | Immunity, Cellular | 1 | 2016 | 263 | 0.120 |
Why?
| | HLA-DR Antigens | 3 | 2008 | 220 | 0.120 |
Why?
| | Polyamines | 1 | 2014 | 39 | 0.120 |
Why?
| | CD56 Antigen | 1 | 2014 | 34 | 0.120 |
Why?
| | Thromboplastin | 1 | 2014 | 71 | 0.120 |
Why?
| | Sequence Analysis, DNA | 1 | 2017 | 733 | 0.120 |
Why?
| | Physical Fitness | 1 | 2015 | 179 | 0.120 |
Why?
| | Adolescent | 6 | 2019 | 17955 | 0.120 |
Why?
| | Lipoproteins, LDL | 1 | 2014 | 129 | 0.110 |
Why?
| | Intestines | 1 | 2017 | 325 | 0.110 |
Why?
| | Amino Acid Sequence | 3 | 2006 | 2000 | 0.110 |
Why?
| | Melanoma | 2 | 2011 | 649 | 0.110 |
Why?
| | Caspase 1 | 1 | 2014 | 141 | 0.110 |
Why?
| | Mucous Membrane | 1 | 2014 | 108 | 0.110 |
Why?
| | Homeostasis | 1 | 2017 | 576 | 0.110 |
Why?
| | Cytomegalovirus Infections | 1 | 2015 | 181 | 0.110 |
Why?
| | Pilot Projects | 1 | 2017 | 1374 | 0.110 |
Why?
| | Cardiovascular Agents | 1 | 2014 | 125 | 0.110 |
Why?
| | Cholesterol, LDL | 1 | 2014 | 309 | 0.100 |
Why?
| | Blood Coagulation | 1 | 2014 | 221 | 0.100 |
Why?
| | Antibodies, Viral | 1 | 2015 | 520 | 0.100 |
Why?
| | Suppressor Factors, Immunologic | 1 | 2011 | 4 | 0.100 |
Why?
| | HIV Seropositivity | 2 | 2019 | 110 | 0.100 |
Why?
| | Molecular Sequence Data | 2 | 2006 | 2793 | 0.100 |
Why?
| | Toll-Like Receptor 4 | 1 | 2013 | 288 | 0.090 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2014 | 446 | 0.090 |
Why?
| | Genes, bcl-2 | 1 | 2010 | 20 | 0.090 |
Why?
| | Exercise | 1 | 2021 | 1611 | 0.090 |
Why?
| | Cell Survival | 1 | 2014 | 1026 | 0.090 |
Why?
| | Motor Activity | 1 | 2015 | 636 | 0.090 |
Why?
| | Disease Progression | 3 | 2019 | 2424 | 0.090 |
Why?
| | Antigens, CD1 | 1 | 2010 | 57 | 0.090 |
Why?
| | Signal Transduction | 2 | 2021 | 4526 | 0.090 |
Why?
| | Cytomegalovirus | 2 | 2015 | 145 | 0.080 |
Why?
| | Cell Separation | 1 | 2010 | 293 | 0.080 |
Why?
| | Double-Blind Method | 2 | 2016 | 1665 | 0.080 |
Why?
| | Reference Standards | 1 | 2009 | 161 | 0.080 |
Why?
| | Glycoproteins | 1 | 2010 | 308 | 0.080 |
Why?
| | Sequence Alignment | 2 | 2006 | 328 | 0.080 |
Why?
| | Mice, Transgenic | 3 | 2016 | 1970 | 0.070 |
Why?
| | HLA-A3 Antigen | 2 | 2004 | 6 | 0.070 |
Why?
| | HLA-A2 Antigen | 2 | 2004 | 38 | 0.070 |
Why?
| | DNA Primers | 1 | 2008 | 513 | 0.070 |
Why?
| | Fluorides | 1 | 2006 | 45 | 0.070 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2007 | 175 | 0.070 |
Why?
| | Polyurethanes | 1 | 2006 | 36 | 0.070 |
Why?
| | Lymphocyte Culture Test, Mixed | 1 | 2006 | 43 | 0.070 |
Why?
| | Membrane Glycoproteins | 2 | 2013 | 429 | 0.070 |
Why?
| | gag Gene Products, Human Immunodeficiency Virus | 1 | 2006 | 12 | 0.070 |
Why?
| | Anti-Infective Agents | 1 | 2009 | 225 | 0.070 |
Why?
| | Methacrylates | 1 | 2006 | 110 | 0.070 |
Why?
| | HIV | 1 | 2007 | 209 | 0.070 |
Why?
| | Receptors, CCR7 | 1 | 2005 | 24 | 0.070 |
Why?
| | Receptors, Chemokine | 1 | 2005 | 43 | 0.070 |
Why?
| | Leukocyte Common Antigens | 1 | 2005 | 75 | 0.070 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2008 | 794 | 0.060 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 2008 | 340 | 0.060 |
Why?
| | Recombination, Genetic | 1 | 2006 | 176 | 0.060 |
Why?
| | Anti-Bacterial Agents | 1 | 2014 | 1486 | 0.060 |
Why?
| | Gene Expression Regulation | 1 | 2014 | 2362 | 0.060 |
Why?
| | Antigenic Variation | 1 | 2004 | 9 | 0.060 |
Why?
| | Beryllium | 1 | 2005 | 146 | 0.060 |
Why?
| | Base Sequence | 1 | 2008 | 2120 | 0.060 |
Why?
| | HLA-B7 Antigen | 1 | 2003 | 8 | 0.060 |
Why?
| | Animals | 6 | 2023 | 32123 | 0.060 |
Why?
| | Longitudinal Studies | 2 | 2018 | 2437 | 0.060 |
Why?
| | Superantigens | 1 | 2003 | 69 | 0.060 |
Why?
| | Histocompatibility Testing | 1 | 2003 | 116 | 0.060 |
Why?
| | Cell Line, Transformed | 1 | 2003 | 133 | 0.060 |
Why?
| | Berylliosis | 1 | 2005 | 177 | 0.060 |
Why?
| | Mutation | 1 | 2014 | 3371 | 0.060 |
Why?
| | Amino Acid Motifs | 1 | 2003 | 198 | 0.060 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2003 | 165 | 0.050 |
Why?
| | B7-2 Antigen | 1 | 2002 | 25 | 0.050 |
Why?
| | Tryptophan | 1 | 2023 | 136 | 0.050 |
Why?
| | Receptors, CCR5 | 1 | 2002 | 54 | 0.050 |
Why?
| | Mice | 4 | 2023 | 15075 | 0.050 |
Why?
| | Receptors, CXCR4 | 1 | 2002 | 78 | 0.050 |
Why?
| | HLA-DRB1 Chains | 1 | 2003 | 99 | 0.050 |
Why?
| | Clone Cells | 1 | 2003 | 247 | 0.050 |
Why?
| | Epitopes | 1 | 2004 | 438 | 0.050 |
Why?
| | CD40 Antigens | 1 | 2002 | 80 | 0.050 |
Why?
| | T-Lymphocytes, Helper-Inducer | 1 | 2003 | 129 | 0.050 |
Why?
| | Cell Division | 1 | 2004 | 760 | 0.050 |
Why?
| | Datasets as Topic | 1 | 2022 | 100 | 0.050 |
Why?
| | Collagen | 1 | 2023 | 415 | 0.050 |
Why?
| | Receptors, Tumor Necrosis Factor, Type II | 1 | 2021 | 34 | 0.050 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 1 | 2003 | 310 | 0.050 |
Why?
| | Histocompatibility Antigens Class II | 1 | 2003 | 352 | 0.050 |
Why?
| | Receptors, Tumor Necrosis Factor, Type I | 1 | 2021 | 73 | 0.050 |
Why?
| | Lipopolysaccharides | 2 | 2014 | 832 | 0.050 |
Why?
| | Genetic Variation | 1 | 2006 | 891 | 0.050 |
Why?
| | Alleles | 1 | 2003 | 818 | 0.040 |
Why?
| | Fatty Acids, Volatile | 1 | 2019 | 47 | 0.040 |
Why?
| | Cohort Studies | 2 | 2010 | 4960 | 0.040 |
Why?
| | Predictive Value of Tests | 1 | 2003 | 1817 | 0.040 |
Why?
| | Inpatients | 1 | 2022 | 380 | 0.040 |
Why?
| | Metagenome | 1 | 2019 | 122 | 0.040 |
Why?
| | Metagenomics | 1 | 2019 | 132 | 0.040 |
Why?
| | Body Composition | 1 | 2021 | 581 | 0.040 |
Why?
| | Protein Binding | 1 | 2003 | 1919 | 0.040 |
Why?
| | Interleukin-6 | 1 | 2021 | 679 | 0.040 |
Why?
| | Symbiosis | 1 | 2017 | 64 | 0.040 |
Why?
| | APOBEC-3G Deaminase | 1 | 2016 | 6 | 0.030 |
Why?
| | Myxovirus Resistance Proteins | 1 | 2016 | 8 | 0.030 |
Why?
| | Bacterial Infections | 1 | 2018 | 222 | 0.030 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2021 | 1138 | 0.030 |
Why?
| | Electroporation | 1 | 2016 | 32 | 0.030 |
Why?
| | Adipose Tissue | 1 | 2019 | 553 | 0.030 |
Why?
| | Cardiovascular Diseases | 2 | 2019 | 1724 | 0.030 |
Why?
| | Placebos | 1 | 2016 | 198 | 0.030 |
Why?
| | Treatment Outcome | 3 | 2014 | 9166 | 0.030 |
Why?
| | Virion | 1 | 2015 | 68 | 0.030 |
Why?
| | Computational Biology | 1 | 2019 | 528 | 0.030 |
Why?
| | Sevelamer | 1 | 2014 | 9 | 0.030 |
Why?
| | Cross-Over Studies | 1 | 2016 | 437 | 0.030 |
Why?
| | Drug Resistance, Viral | 1 | 2014 | 99 | 0.030 |
Why?
| | ADP-ribosyl Cyclase 1 | 1 | 2013 | 36 | 0.030 |
Why?
| | Treatment Failure | 1 | 2014 | 333 | 0.030 |
Why?
| | Prospective Studies | 1 | 2004 | 6267 | 0.030 |
Why?
| | Liver | 1 | 2019 | 1693 | 0.020 |
Why?
| | Diet | 1 | 2019 | 1075 | 0.020 |
Why?
| | Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2011 | 44 | 0.020 |
Why?
| | Culture Media, Conditioned | 1 | 2011 | 105 | 0.020 |
Why?
| | Myocardial Infarction | 1 | 2018 | 930 | 0.020 |
Why?
| | Immunoglobulin G | 1 | 2015 | 782 | 0.020 |
Why?
| | Endocytosis | 1 | 2011 | 152 | 0.020 |
Why?
| | Stroke | 1 | 2018 | 1014 | 0.020 |
Why?
| | Drug Administration Schedule | 1 | 2011 | 724 | 0.020 |
Why?
| | Odds Ratio | 1 | 2011 | 969 | 0.020 |
Why?
| | Drug Therapy, Combination | 1 | 2011 | 961 | 0.020 |
Why?
| | Lymphocyte Count | 1 | 2008 | 132 | 0.020 |
Why?
| | Antibodies, Blocking | 1 | 2007 | 32 | 0.020 |
Why?
| | Medication Adherence | 1 | 2011 | 536 | 0.020 |
Why?
| | B7-H1 Antigen | 1 | 2007 | 138 | 0.020 |
Why?
| | Transforming Growth Factor beta | 1 | 2008 | 447 | 0.020 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2007 | 193 | 0.020 |
Why?
| | Ligands | 1 | 2007 | 568 | 0.020 |
Why?
| | Selection Bias | 1 | 2005 | 33 | 0.020 |
Why?
| | Survivors | 1 | 2008 | 405 | 0.020 |
Why?
| | Lymph Nodes | 1 | 2007 | 422 | 0.020 |
Why?
| | Gene Products, env | 1 | 2004 | 7 | 0.020 |
Why?
| | Gene Products, pol | 1 | 2004 | 6 | 0.020 |
Why?
| | Neoplasms | 1 | 2018 | 2112 | 0.020 |
Why?
| | Genes, MHC Class I | 1 | 2004 | 32 | 0.010 |
Why?
| | Up-Regulation | 1 | 2007 | 824 | 0.010 |
Why?
| | Survival Rate | 1 | 2008 | 1653 | 0.010 |
Why?
| | Amino Acid Substitution | 1 | 2004 | 267 | 0.010 |
Why?
| | Peptide Fragments | 1 | 2004 | 675 | 0.010 |
Why?
| | Research Design | 1 | 2005 | 947 | 0.010 |
Why?
| | Algorithms | 1 | 2004 | 1494 | 0.010 |
Why?
| | Lung | 1 | 2005 | 3685 | 0.010 |
Why?
|
|
Wilson's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|